Interleukin-35 expression protects against cigarette smoke-induced lung inflammation in mice

Biomed Pharmacother. 2019 Feb:110:727-732. doi: 10.1016/j.biopha.2018.12.028. Epub 2018 Dec 13.

Abstract

Cigarette smoke (CS) is a very important cause of pulmonary inflammatory diseases. Interleukin (IL)-35 is a novel anti-inflammatory cytokine but its role in CS-mediated lung inflammation remains unclear. In the present study, we examined the effect of IL-35 expression on CS-induced lung inflammation in mice. A plasmid DNA expressing IL-35 was injected into mice via a hydrodynamic-based gene delivery that were subsequently exposed to CS three times a day for 5 days. We found that IL-35 expression inhibited pulmonary inflammatory infiltration, lung tissue lesions, mucus secretion, and myeloperoxidase activity in CS-treated mice. Moreover, IL-35 expression decreased the production of IL-1β, tumor necrosis factor-α, IL-6, and IL-17, but increased the level of IL-10 in bronchoalveolar lavage fluids and lung tissues from CS-challenged mice. These results suggest that in vivo expression of IL-35 can protect against CS-induced lung inflammation and may be a therapeutic target in CS-related pulmonary diseases.

Keywords: Cigarette smoke; Hydrodynamic-based gene delivery; IL-35; Lung inflammation.

MeSH terms

  • Animals
  • Cigarette Smoking / adverse effects*
  • Gene Expression
  • Inhalation Exposure / adverse effects
  • Interleukins / biosynthesis*
  • Interleukins / genetics
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Pneumonia / chemically induced
  • Pneumonia / metabolism*
  • Pneumonia / prevention & control*
  • Smoke / adverse effects*

Substances

  • Interleukins
  • Smoke
  • interleukin-35, mouse